Abstract
Introducción: Optic neuromyelitis, a clinical syndrome characterized by the association of transverse myelitis and optic neuritis, is nowadays recognized as a disease whose pathophysiology, clinical features, and diagnostic and laboratory imaging findings are specific.
Objective: To describe the clinical characteristics, diagnostic methods and treatment of patients with neuromyelitis Optica (NMO) in three health centers fourth level of the City of Bogota.
Materials and method: Design: A case series type was performed. Participants: consecutive cases of patients of either gender were included between 19 and 48 years, divided into two groups according to the International Consensus criteria for the diagnosis of NMO 2015, NMOSD with AQP4-IgG positive, and NMOSD with AQP4- IgG negative. Patients were recruited from three hospitals from June 2013 to May 2015. Statistical analysis: The description of the variables was performed by absolute and relative frequencies, analyzes were performed in STATA statistical package 13®.
Results: A total of 22 patients with a median age of 36, mostly women, median onset was 31 years (IQR 24-39). The technique most commonly used for diagnosis was IFI, the most frequent initial clinical event was myelitis and optic neuritis in subsequent relapses, half of the patients had two or fewer events, no patients met criteria for other systemic disease. higher disability scales were observed in the group with positive AQP4, and lower in those receiving corticosteroids at baseline.
Discussion and conclusions: This characterization is the first description of this disease in Colombia, our findings are similar to those obtained in other populations, some relevant data require further study.
References
Pinzón A, Echeverry T, Rodríguez AB. Neuromielitis óptica (enfermedad de Devic). Acta. Med. Colomb. 2010;35(1):21-5.
Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol. 2002;22(2):105-22.
Weinshenker BG. Neuromyelitis optica: what it is and what it might be. Lancet. 2003;361(9361):889-90.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-15.
Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-14.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-9.
Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: A review Mult Scler. 2015;21(7):845-53.
Kuroiwa Y, Igata A, Itahara K, Koshijima S, Tsubaki T. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology. 1975;25(9):845-51.
Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256(1):35-44.
Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589-95.
Rivera JF, Kurtzke JF, Booth VJ, Corona V T. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol. 2008;255(5):710-5.
Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O, Bellance R, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology. 2001;56(4):507-14.
Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol. 2013;260(8):2134-7.
Pandit L, Kundapur R. Prevalence and patterns of demyelinat-ing central nervous system disorders in urban Mangalore, South India. Mult Scler. 2014;20(12):1651-3.
Bichuetti DB, Oliveira EM, Souza NA, Rivero RL, Gabbai AA. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler. 2009;15(5):613-9.
Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-80.
Erwin Chiquete JN-B, Raúl Ayala-Armas, Noé Gutiérrez-Gutiérrez,, Alejandro Solórzano-Meléndez DR-T, Marianela Gómez-Rincón, José L. Ruiz-Sandoval. Neuromielitis óptica: actualización clínica. Rev Neurol. 201O;51(5):289-94.
Vanda A Lennon DMW, Thomas Kiyzer. Sean Pittock. Ooudia F Lucchmetti. Kazuo fujiharo, Ichiro Nakashima. Brian G Weinshcnkcr. A serum autoantibody marker of neu-romyelitis optica: distinction from multiple sclerosis. The lancet. 2004;364(9451):2106-12.
Ayuga-Loro F, Teijeira-Azcona A. [Clinical variability in neuromyelitis optica: three case reports]. Rev Neurol. 2011;52(3):154-8.
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-7.
Sebastián de la Cruz F, López-Dolado E. [Devic's optic neuromyelitis: analysis of 7 cases]. Rev Neurol. 1999;28(5):476-82.
Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535-44.
Hervás-García JV, Grau-López L, Doménech-Puigcerver S, Ramo-Tello C. [Encephalopathy and neuromyelitis optica: the importance of recognising atypical symptoms]. Rev Neurol. 2014;58(1):20-4.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W Chit-nis T, et al. International consensus diagnostic criteria for neuro-myelitis optica spectrum disorders. Neurology. 2015;85(2):177-89.
Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin. 2005;23(1):17-38.
Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9(número):14.
Collongues N, Marignier R, Jacob A, Leite M, Siva A, Paul F, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2013;20(8):1086-94.
Siritho S, Nakashima I, Takahashi T, Fujihara K, Prayoonwiwat N. AQP4 antibody-positive Thai cases: clinical features and diagnostic problems. Neurology. 2011;77(9):827-34.
Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F, et al. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol. 2007;254(9):1233-7.
Pittock SJ. Neuromyelitis optica: a new perspective. Semin Neurol. 2008;28(1):95-104.
Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol. 2008;318(número):343-56.
Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008;5(número):22.
Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Naka-mura M, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry. 2006;77(9):1073-5.
Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78-83.
Echevarría G, Tróccolli G, D'Annuncio E, Gutiérrez O. [Devic's optic neuromyelitis: presentation as an inflammatory spinal tumour]. Rev Neurol. 2001;33(1):41-4.
Sergio P, Mariana B, Alberto O, Claudia U, Oscar R, Pablo M, et al. Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature. Clin Rheumatol. 2010;29(11):1335-8.
Ruiz-Gaviria R, Baracaldo I, Castañeda C, Ruiz-Patiño A, Acosta-Hernandez A, Rosselli D. Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: A meta-analysis. Mult Scler Relat Disord. 2015;4(4):345-9.
Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-81.
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63(3):390-6.
Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 1i):2059-69.
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964-8.
Anu Jacob M, MRCP, DM, Brian G. Weinshenker M, Ivo Violich B. Treatment of Neuromyelitis OpticaWith Rituximab. Arch Neurol. 2008;65(11):1443-8.
Fernández-Megía MJ, Casanova-Estruch B, Pérez-Miralles F, Ruiz-Ramos J, Alcalá-Vicente C, Poveda-Andrés JL. Clinical evaluation of rituximab treatment for neuromyelitis optica. Neurologia. 2015;30(8):461-4.
Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13(2):256-9.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.